Literature DB >> 25398389

[Vancouver classification of renal tumors: Recommendations of the 2012 consensus conference of the International Society of Urological Pathology (ISUP)].

G Kristiansen1, B Delahunt, J R Srigley, C Lüders, J-M Lunkenheimer, H Gevensleben, T Thiesler, R Montironi, L Egevad.   

Abstract

The 2012 consensus conference of the International Society of Urological Pathology (ISUP) has formulated recommendations on classification, prognostic factors and staging as well as immunohistochemistry and molecular pathology of renal tumors. Agreement was reached on the recognition of five new tumor entities: tubulocystic renal cell carcinoma (RCC), acquired cystic kidney disease-associated RCC, clear cell (tubulo) papillary RCC, microphthalmia transcription factor family RCC, in particular t(6;11) RCC and hereditary leiomyomatosis-associated RCC. In addition three rare forms of carcinoma were considered as emerging or provisional entities: thyroid-like follicular RCC, succinate dehydrogenase B deficiency-associated RCC and anaplastic lymphoma kinase (ALK) translocation RCC. In the new ISUP Vancouver classification, modifications to the existing 2004 World Health Organization (WHO) specifications are also suggested. Tumor morphology, a differentiation between sarcomatoid and rhabdoid and tumor necrosis were emphasized as being significant prognostic parameters for RCC. The consensus ISUP grading system assigns clear cell and papillary RCCs to grades 1-3 due to nucleolar prominence and grade 4 is reserved for cases with extreme nuclear pleomorphism, sarcomatoid and/or rhabdoid differentiation. Furthermore, consensus guidelines were established for the preparation of samples. For example, agreement was also reached that renal sinus invasion is diagnosed when the tumor is in direct contact with the fatty tissue or loose connective tissue of the sinus (intrarenal peripelvic fat) or when endothelialized cavities within the renal sinus are invaded by the tumor, independent of the size. The importance of biomarkers for the diagnostics or prognosis of renal tumors was also emphasized and marker profiles were formulated for use in specific differential diagnostics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25398389     DOI: 10.1007/s00292-014-2030-z

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  24 in total

1.  Renal tumors associated with germline SDHB mutation show distinctive morphology.

Authors:  Anthony J Gill; Nicholas S Pachter; Angela Chou; Barbara Young; Adele Clarkson; Katherine M Tucker; Ingrid M Winship; Peter Earls; Diana E Benn; Bruce G Robinson; Stewart Fleming; Roderick J Clifton-Bligh
Journal:  Am J Surg Pathol       Date:  2011-10       Impact factor: 6.394

2.  The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia.

Authors:  John R Srigley; Brett Delahunt; John N Eble; Lars Egevad; Jonathan I Epstein; David Grignon; Ondrej Hes; Holger Moch; Rodolfo Montironi; Satish K Tickoo; Ming Zhou; Pedram Argani
Journal:  Am J Surg Pathol       Date:  2013-10       Impact factor: 6.394

3.  Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia.

Authors:  Satish K Tickoo; Mariza N dePeralta-Venturina; Lara R Harik; Heath D Worcester; Mohamed E Salama; Andrew N Young; Holger Moch; Mahul B Amin
Journal:  Am J Surg Pathol       Date:  2006-02       Impact factor: 6.394

4.  Handling and reporting of nephrectomy specimens for adult renal tumours: a survey by the European Network of Uropathology.

Authors:  Ferran Algaba; Brett Delahunt; Daniel M Berney; Philippe Camparo; Eva Compérat; David Griffiths; Glen Kristiansen; Antonio Lopez-Beltran; Guido Martignoni; Holger Moch; Rodolfo Montironi; Murali Varma; Lars Egevad
Journal:  J Clin Pathol       Date:  2011-09-30       Impact factor: 3.411

5.  Pure epithelioid PEComas (so-called epithelioid angiomyolipoma) of the kidney: A clinicopathologic study of 41 cases: detailed assessment of morphology and risk stratification.

Authors:  Nalan Nese; Guido Martignoni; Christopher D Fletcher; Ruta Gupta; Chin-Chan Pan; Hyung Kim; Jae Y Ro; Il S Hwang; Katsuaki Sato; Franco Bonetti; Maurizio Pea; Mitual B Amin; Ondrej Hes; Alexandr Svec; Masatoshi Kida; Mahesha Vankalakunti; Dror Berel; Andre Rogatko; Allen M Gown; Mahul B Amin
Journal:  Am J Surg Pathol       Date:  2011-02       Impact factor: 6.394

6.  Molecular confirmation of t(6;11)(p21;q12) renal cell carcinoma in archival paraffin-embedded material using a break-apart TFEB FISH assay expands its clinicopathologic spectrum.

Authors:  Pedram Argani; Raluca Yonescu; Laura Morsberger; Kerry Morris; George J Netto; Nathan Smith; Nilda Gonzalez; Peter B Illei; Marc Ladanyi; Constance A Griffin
Journal:  Am J Surg Pathol       Date:  2012-10       Impact factor: 6.394

7.  Identification and characterization of Birt-Hogg-Dubé associated renal carcinoma.

Authors:  T Murakami; F Sano; Y Huang; A Komiya; M Baba; Y Osada; Y Nagashima; K Kondo; N Nakaigawa; T Miura; Y Kubota; M Yao; T Kishida
Journal:  J Pathol       Date:  2007-04       Impact factor: 7.996

8.  Tubulocystic carcinoma of the kidney: a new entity among renal tumors.

Authors:  Sandy Azoulay; Annick Vieillefond; François Paraf; Dominique Pasquier; Olivier Cussenot; Patrice Callard; Mathilde Sibony
Journal:  Virchows Arch       Date:  2007-09-05       Impact factor: 4.064

9.  Tubulocystic carcinoma of the kidney: clinicopathologic analysis of 31 cases of a distinctive rare subtype of renal cell carcinoma.

Authors:  Mahul B Amin; Gregory T MacLennan; Ruta Gupta; David Grignon; Francois Paraf; Annick Vieillefond; Gladell P Paner; Mark Stovsky; Andrew N Young; John R Srigley; John C Cheville
Journal:  Am J Surg Pathol       Date:  2009-03       Impact factor: 6.394

10.  Tubulocystic carcinoma of the kidney: clinicopathologic and molecular characterization.

Authors:  Ximing J Yang; Ming Zhou; Ondrej Hes; Steven Shen; Rongshan Li; Jose Lopez; Rajal B Shah; Yu Yang; Shang-Tian Chuang; Fan Lin; Maria M Tretiakova; Eric J Kort; Bin Tean Teh
Journal:  Am J Surg Pathol       Date:  2008-02       Impact factor: 6.394

View more
  7 in total

Review 1.  [Oncocytoma versus chromophobe renal cell carcinoma: Is there something in between?].

Authors:  C Lüders; G Kristiansen
Journal:  Pathologe       Date:  2016-03       Impact factor: 1.011

2.  [Succinate dehydrogenase (SDH)-deficient renal cell carcinoma].

Authors:  A Agaimy
Journal:  Pathologe       Date:  2016-03       Impact factor: 1.011

Review 3.  [Histological subtypes of renal cell carcinoma : Overview and new developments].

Authors:  I Polifka; A Agaimy; H Moch; A Hartmann
Journal:  Pathologe       Date:  2021-04-06       Impact factor: 1.011

4.  SETD2, GIGYF2, FGFR3, BCR, KMT2C, and TSC2 as candidate genes for differentiating multilocular cystic renal neoplasm of low malignant potential from clear cell renal cell carcinoma with cystic change.

Authors:  Sung Han Kim; Weon Seo Park; Jinsoo Chung
Journal:  Investig Clin Urol       Date:  2019-04-01

5.  A Comprehensive Commentary on the Multilocular Cystic Renal Neoplasm of Low Malignant Potential: A Urologist's Perspective.

Authors:  Tomas Pitra; Kristyna Pivovarcikova; Reza Alaghehbandan; Adriena Bartos Vesela; Radek Tupy; Milan Hora; Ondrej Hes
Journal:  Cancers (Basel)       Date:  2022-02-06       Impact factor: 6.639

6.  Multilocular Cystic Renal Neoplasm of Low Malignant Potential: A Case Report and Literature Review.

Authors:  Jihyun Lee; Dong Won Kim; Joo Yeon Song; Seong Kuk Yoon
Journal:  Taehan Yongsang Uihakhoe Chi       Date:  2021-07-28

Review 7.  Immune checkpoint inhibitors in renal cell carcinoma.

Authors:  Kirsty Ross; Rob J Jones
Journal:  Clin Sci (Lond)       Date:  2017-10-27       Impact factor: 6.124

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.